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LETTER TO THE EDITOR
New randomized trial of probiotics in pancreatitis needed?
Caution advised
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Dear Sir,
We support the use of large-scale, high-quality, placebo-
controlled randomized trials as much as Dr. Sun and co-
workers do [1]. However, we do not support their rather
strong conclusion that a new randomized trial of probiotic
prophylaxis in patients with predicted severe acute pancre-
atitis is currently warranted.
In their meta-analysis, Sun et al. detected no significant
effects of probiotic prophylaxis in patients with acute
pancreatitis [1]. In our double-blind study on the effect of
combined probiotic strains, which had a sample size almost
five times larger than the previous studies, we detected a
significant increase in both mortality and bowel ischemia
[2]. These were all well-reputed probiotic strains that had
been used for a long time without any negative effects
being reported. The major difference between our study and
the previous three studies is the much larger number of
patients with concurrent organ failure. In their studies, Olah
et al. included only four and 14 patients with multiorgan
failure, respectively [3, 4]. In contrast, our study included
64 patients with organ failure, including 48 patients with
multiorgan failure with no significant differences at
baseline between the groups [2]. The unexpected effect of
probiotics in our study, i.e., nine cases of bowel ischemia
including eight with fatal outcome, was solely present in
patients with organ failure receiving probiotics. The sample
size of the previous studies was obviously too small to
detect the apparent potential negative effects of probiotics
in patients with acute pancreatitis and concurrent organ
failure.
In their discussion, Sun et al. suggest that the
randomization in our study was “skewed” for organ
failure. Their conclusion is based on their own post hoc
calculation deducting patients that developed organ failure
“on the day of randomization” from the total number of
patients with organ failure. However, as explained in our
manuscript [2], many patients that developed organ failure
“on the day of randomization” had, by that time, already
received one or two doses of probiotics. Therefore, the
onset of organ failure “on the day of randomization” cannot
be used as a parameter to conclude that randomization was
“skewed.” Furthermore, there were no significant differ-
ences between the groups in any of the baseline character-
istics. After correcting for the minor imbalances in organ
failure and pancreatic necrosis present at baseline, mortality
remained higher in the probiotics group. Finally, when
excluding all patients with organ failure “on the day of
randomization” from the analysis, mortality was still twice
as high in the probiotics group and a significantly higher
proportion of patients developed bowel ischemia in the
probiotics group.
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Notably, in Fig. 3 of their paper, Sun et al. misquote the
first study of Olah et al. [3] by stating that there was a
decrease in incidence of systemic inflammatory response
syndrome (SIRS) due to probiotic treatment: 41% SIRS
(9/22) in the probiotics group vs 48% (11/23) in the
control-group. Table 3 in the original paper reveals
different data: 50% SIRS (11/22) in the probiotics group
vs 26% (6/23) in the control group; the risk of SIRS was
actually increased in patients receiving probiotics.
Our group has recently started experimental studies
focusing on the impact of probiotic treatment in the
hypoperfused gut. In a field where currently so many
factors remain unclear, we would suggest the highest level
of caution in launching any new randomized trial of
probiotic prophylaxis in patients with predicted severe
acute pancreatitis. We realize that one large trial, in general,
is usually not sufficient to fully discard a certain treatment
for an important indication as severe acute pancreatitis.
However, we strongly disagree with their conclusion which
is based on a meta-analysis in which three of the four
studies have serious methodological shortcomings and one
well-designed study shows a significantly higher mortality
after probiotic treatment without an acceptable explanation
at this stage.
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